---
title: "Cybin Inc. (HELP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HELP.US.md"
symbol: "HELP.US"
name: "Cybin Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-21T17:38:55.352Z"
locales:
  - [en](https://longbridge.com/en/quote/HELP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HELP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HELP.US.md)
---

# Cybin Inc. (HELP.US)

## Company Overview

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [cybin.com](https://cybin.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.76 | 127 | - | - | - |
| PB | 0.79 | 35 | 2.38 | 1.01 | 0.91 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-13T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.59 |
| Highest Target | 93.50 |
| Lowest Target | 7.99 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HELP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HELP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HELP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HELP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**